Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

NCT02530008 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT02530008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02530008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Active, not recruiting
Start date
October 31, 2013
Completion date
October 31, 2026
Enrollment
600 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

women with suspected or confirmed recurrent breast cancer